A recent study (A Ricciuto et al. Clin Gastroenterol Hepatol 2018; 16: 1098-1105) provides more data regarding the lack of symptom correlation and inflammatory bowel disease (IBD) activity in children with primary sclerosing cholangitis (PSC).
In a prospective study of children with colonic IBD with and without PSC, the authors followed clinical features (eg. PUCAI), fecal calprotectin and endoscopy severity.
- Patients with PSC-IBD (n=37) in clinical remission had higher endoscopic scores and greater odd of active endoscopic disease than IBD-only controls (n=50) (odds ratio 5.9, with CI 1.6-21.5)
- Fecal calprotectin level <93 mcg/g were identified mucosal healing with 100% sensitivity and 92% specificity when compared with UC Endoscopic Index of Severity (UCEIS)
Overall, this study is in agreement with a prior adult study showing higher levels of active disease in those with PSC-IBD compared to those with IBD alone, despite clinical remission (Why does PSC increase the risk of colorectal cancer in UC?).
My take: Particularly in individuals with the combination of IBD-PSC, objective biomarkers (eg. Calprotectin) are needed to identify the accuracy of clinical remission; though, even in patients with IBD without PSC, objective biomarkers are needed as well due to the limitations of clinical symptom indices.
Related blog posts:
Two complementary articles provide extensive guidance on the management of ulcerative colitis and acute severe colitis:
- D Turner et al. JPGN 2018; 67: 257-91
- D Turner et al. JPGN 2018; 67: 292-310
Between the two articles there are more than 60 practice recommendations, more than 120 practice points, and more than 700 references. As such, these articles are probably better for a journal review meeting rather than a brief blog post.
Figure 1 (2nd article, page 299) provides a handy algorithm for management of acute severe colitis:
- On day 1-2, the algorithm recommends stool studies, starting methylprednisolone, and withholding 5-ASA.
- On day 3, if PUCAI <45, suggests continuing steroid and transitioning to oral therapy when PUCAI <35. On day 3, if PUCAI ≥45, the authors suggest screening for second line therapy, involve surgery (to discuss colectomy if there is nonresponse to medical treatment), and looking for CMV infection (eg. sigmoidoscopy).
- On day 5, if PUCAI >65, recommendation is to start 2nd line Rx (eg. infliximab, tacrolimus, or cyclosporine). If PUCAI 35-65, continue corticosteroids for additional 2-5 days. The authors note that infliximab is preferred 2nd line Rx unless planning to transition to vedolizumab.
- The authors recommend weaning corticosteroids when 2nd line Rx is started
- The authors recommend addition of an immunomodulator for at least 6 months in responders to infliximab in effort to lower the risk of colectomy.
- The authors state “urgent colectomy is recommended following failure of 1 second-line therapy.”
Disclaimer: These blog posts are for educational purposes only. Specific dosing of medications/diets (along with potential adverse effects) should be confirmed by prescribing physician/nutritionist. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.
Related blog posts:
- An overlooked finding in a recent acute severe ulcerative colitis study
- UC SUCCESS
- Infliximab for children with Ulcerative Colitis
- Accelerated Infliximab Dosing in Acute … – gutsandgrowth
- Predictors of colectomy in pediatric UC | gutsandgrowth
- Predicting Remission in Pediatric Ulcerative Colitis …
A recent retrospective study (W El-Matary et al. JPGN 2018; 67: 221-24) examined the practice of looking for Cytomegalovirus (CMV) in children with a flareup of their inflammatory bowel disease (IBD) which is currently recommended by expert consensus (JPGN 2018; 67: 292-310 –recommendation #3).
- “Four of 61 patients encounters (6.6%) with UC/IBD-U, two with corticosteroid refractory disease, had positive biopsies for CMV by PCR but negative H&E and IHC. They responded to escalated medical therapy, without needing anti-viral therapy.”
- All children who had colectomy during the study did not have CMV detected in colonic mucosa.
The authors note that the rationale for looking for CMV is derived mainly from adult populations. Since age is a known risk factor for CMV reactivation, the risk of CMV causing refractory IBD in children is less.
My take (borrowed in part from authors): “The low frequency of CMV in our study challenges current guidelines that recommend assessment for CMV in all pediatric patients with acute severe UC refractory to corticosteroids.” This issue would be another that would benefit by collecting the experience of a large cohort (eg. ICN).
Related blog posts:
- Will infliximab worsen flare-ups associated with CMV? (Not in this study)
- CMV in IBD: Tissue Matters | gutsandgrowth
- IBD Updates -January 2017 | gutsandgrowth
- Utility of Antiviral Therapy for Cytomegalovirus in the … – gutsandgrowth
Disclaimer: These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.
Briefly noted: A recent study (EA Spencer et al.Inflamm Bowel Dis 2018; 24: 1335-42) examined phenotype and serology in 399 children with newly diagnosed ulcerative colitis (PROTECT study).
- 65% had positive serology for pANCA; 62% in those <12 and 66% in those ≥12 years
- 19% had positive serology for anti-CBir1; 32% in those <12 and 14% in those ≥12 years
- High titer (≥ 100)) pANCA positivity was associated with more extensive disease but not with PUCAI values or Mayo endoscopic subscores.
My take: The serology titers for IBD, in my view, have academic interest but do not routinely enhance patient care.
Related blog post:
- Low-Value Care: IBD Serologies for Diagnosis of IBD
- How helpful are serologies in pediatric inflammatory bowel disease?
A presentation at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO, Feb 2018) indicated that Vedolizumab had similar effectiveness as anti-TNF agents for both ulcerative colitis and Crohn’s disease. This data has been presented at a recent meeting in our office, some of the GI news magazines, and also ImproveCareNow listserv.
From Takeda website: Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease Patients in Comparative Effectiveness Real-World Data Analysis
These analyses observed that patients with UC treated with Entyvio compared to TNFα-antagonist therapy had statistically significant higher 12-month cumulative rates of mucosal healing (50% vs 42%, hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.10‑2.73) and clinical remission (54% vs 37%; HR 1.54, 95% CI 1.08‑2.18), and numerically higher steroid-free clinical remission rates (49% vs 38%; HR 1.43, 95% CI 0.79‑2.60). In CD, results reported statistically significant higher 12-month cumulative rates of mucosal healing (50% vs 41%; HR 1.67, 95% CI 1.13‑2.47), and numerically higher rates of clinical remission (38% vs 34%; HR 1.27, 95% CI 0.91‑1.78) and steroid-free clinical remission (26% vs 18%; HR 1.75, 95% CI 0.90‑3.43) compared to TNFα-antagonist therapy. These analyses were conducted by the VICTORY (Vedolizumab Health OuTComes in InflammatORY Bowel Diseases) Consortium.
My take: While the data compare anti-TNFs to vedolizumab in a “real-world setting,” the reported outcomes for anti-TNFs are lower than in other studies. Vedolizumab had the best results in those with colonic disease. Patients with Crohn’s disease with isolated small bowel disease had lower response rates.
Related study: AK Waljee et al Inflamm Bowel Dis 2018; 24: 1185-95. Using phase 3 clinical trial data with 594 subjects, the authors note that the majority of patients who will respond to vedolizumab can be identified by week 6 using a laboratory algorithm based on hemoglobin, albumin, vedolizumab level and CRP. Fformula: Hgb*Albumin*VDZ level/CRP*Weight. A cutoff of 185.96 predicted success with an AuROC of 0.75. Higher hemoglobin, higher albumin, and higher vedolizumab level, and lower CRP are associate with higher response rates.
Related blog posts:
- Summary of latest information on Vedolizumab
- GI Care for Kids Data on Vedolizumab 2017
- Latest on Vedolizumab
- Pediatric Experience with Vedolizumab | gutsandgrowth
- Vedolizumab -another new IBD treatment | gutsandgrowth